These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 22803615

  • 1. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen YK, Leonardi C, PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups.
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [Abstract] [Full Text] [Related]

  • 2. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.
    Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G.
    Br J Dermatol; 2014 Oct; 171(4):884-90. PubMed ID: 24863903
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C, Dehesa L, Vega A, Kerdel F.
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators.
    Lancet; 2008 May 17; 371(9625):1665-74. PubMed ID: 18486739
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
    Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K.
    J Am Acad Dermatol; 2012 May 17; 66(5):742-51. PubMed ID: 21978572
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group.
    J Dermatol; 2012 Mar 17; 39(3):242-52. PubMed ID: 21955098
    [Abstract] [Full Text] [Related]

  • 12. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV, Exter BP, Steinberg M, Jarvis CI.
    Ann Pharmacother; 2009 Sep 17; 43(9):1456-65. PubMed ID: 19671802
    [Abstract] [Full Text] [Related]

  • 13. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
    Conti A, Piaserico S, Gisondi P, Odorici G, Galdo G, Lasagni C, Pellacani G.
    Dermatol Ther; 2017 Sep 17; 30(5):. PubMed ID: 28547750
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
    Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, Davis HM.
    J Clin Pharmacol; 2010 Mar 17; 50(3):257-67. PubMed ID: 19934030
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
    Br J Dermatol; 2012 Apr 17; 166(4):861-72. PubMed ID: 22356258
    [Abstract] [Full Text] [Related]

  • 17. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
    Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, Goyal K, Schenkel B, Giles-Komar J, Mascelli MA, Guzzo C.
    Ann N Y Acad Sci; 2012 Aug 17; 1263():1-12. PubMed ID: 22823582
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug 17; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.